![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Broad agreement on pivotal Phase 3 study plan, including use of current amezalpat dose and scheduleOverall survival, the strongest result from the Phase 2 trial, will be the primary study...
Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma (“HCC”) study demonstrating: Survival benefit maintained across key...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0316 | 2.43639167309 | 1.297 | 1.361 | 1.2876 | 1456 | 1.35000541 | DE |
4 | -0.0012 | -0.0902391337043 | 1.3298 | 1.45 | 1.2102 | 9266 | 1.29372897 | DE |
12 | -0.2164 | -14.0064724919 | 1.545 | 1.5512 | 1.2102 | 8645 | 1.37331178 | DE |
26 | -0.4804 | -26.5561083472 | 1.809 | 2.594 | 1.2102 | 10020 | 1.69049391 | DE |
52 | -3.7964 | -74.076097561 | 5.125 | 6.19 | 1.2102 | 8177 | 2.33282985 | DE |
156 | -3.7964 | -74.076097561 | 5.125 | 6.19 | 1.2102 | 8177 | 2.33282985 | DE |
260 | -3.7964 | -74.076097561 | 5.125 | 6.19 | 1.2102 | 8177 | 2.33282985 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions